Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + S-1 (Henan Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Apatinib + S-1 is a combination therapy regimen being evaluated for the treatment of advanced or metastatic colorectal cancer. Apatinib is an oral, small-molecule tyrosine kinase inhibitor that highly selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting tumor angiogenesis. S-1 is an oral fluoropyrimidine chemotherapy agent consisting of tegafur (a 5-fluorouracil prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (an orotate phosphoribosyltransferase inhibitor). This combination was studied in a Phase II trial led by Henan Cancer Hospital as a third-line treatment option for patients who had failed second-line chemotherapy. The regimen aims to combine the anti-angiogenic effects of apatinib with the cytotoxic effects of S-1 to improve outcomes in refractory colorectal cancer populations.
- Other names
- apatinib plus S-1apatinib and S-1
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)OPRT (Orotidine 5'-phosphate decarboxylase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on apatinib + S-1 (Henan Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + S-1 (Henan Cancer Hospital).